{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:20:42Z","timestamp":1790889642561,"version":"4.1.0"},"reference-count":31,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:p>Background. Clinical trials evaluating the use of erythropoietin (Epo) have demonstrated a limited reduction in transfusions; however, long-term developmental follow-up data are scarce.<\/jats:p><jats:p>Objective. We compared anthropometric measurements, postdischarge events, need for transfusions, and developmental outcomes at 18 to 22 months' corrected age in extremely low birth weight (ELBW) infants treated with early Epo and supplemental iron therapy with that of placebo\/control infants treated with supplemental iron alone.<\/jats:p><jats:p>Methods. The National Institute of Child Health and Human Development Neonatal Research Network completed a randomized, controlled trial of early Epo and iron therapy in preterm infants \u22641250 g. A total of 172 ELBW (\u22641000-g birth weight) infants were enrolled (87 Epo and 85 placebo\/control). Of the 72 Epo-treated and 70 placebo\/control ELBW infants surviving to discharge, follow-up data (growth, development, rehospitalization, transfusions) at 18 to 22 months' corrected age were collected on 51 of 72 Epo-treated infants (71%) and 51 of 70 placebo\/controls (73%) by certified examiners masked to the treatment group. Statistical significance was determined using \u03c72 analysis.<\/jats:p><jats:p>Results. There were no significant differences between treatment groups in weight or length or in the percentage of infants weighing &amp;lt;10th percentile either at the time of discharge or at follow-up, and no difference was found in the mean head circumference between groups. A similar percentage of infants in each group was rehospitalized (38% Epo and 35% placebo\/control) for similar reasons. There were no differences between groups with respect to the percentage of infants with Bayley-II Mental Developmental Index &amp;lt;70 (34% Epo and 36% placebo\/control), blindness (0% Epo and 2% placebo\/control), deafness or hearing loss requiring amplification (2% Epo and 2% placebo\/control), moderate to severe cerebral palsy (16% Epo and 18% placebo\/control) or the percentage of infants with any of the above-described neurodevelopmental impairments (42% Epo and 44% placebo\/control).<\/jats:p><jats:p>Conclusions. Treatment of ELBW infants with early Epo and iron does not significantly influence anthropometric measurements, need for rehospitalization, transfusions after discharge, or developmental outcome at 18 to 22 months' corrected age.<\/jats:p>","DOI":"10.1542\/peds.2003-1129-l","type":"journal-article","created":{"date-parts":[[2004,11,5]],"date-time":"2004-11-05T17:23:11Z","timestamp":1099675391000},"page":"1287-1291","source":"Crossref","is-referenced-by-count":112,"title":["Neurodevelopmental Outcome and Growth at 18 to 22 Months' Corrected Age in Extremely Low Birth Weight Infants Treated With Early Erythropoietin and Iron"],"prefix":"10.1542","volume":"114","author":[{"given":"Robin K.","family":"Ohls","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Ehrenkranz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhik","family":"Das","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Dusick","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Indiana University, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Yolton","sequence":"additional","affiliation":[{"name":"Newborn Center, University of Tennessee, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Romano","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Delaney-Black","sequence":"additional","affiliation":[{"name":"Division of Neonatal and Perinatal Medicine, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Ann","family":"Papile","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal P.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean J.","family":"Steichen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly G.","family":"Lee","sequence":"additional","affiliation":[{"name":"Joint Program in Neonatology, Harvard University, Boston, Massachusetts"},{"name":"National Institute of Child Health and Human Development, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the National Institute of Child Health and Human Development Neonatal Research Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,11,1]]},"reference":[{"key":"2021120819335477000_R1","doi-asserted-by":"crossref","unstructured":"Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics.\u20082001;108:934\u2013942","DOI":"10.1542\/peds.108.4.934"},{"key":"2021120819335477000_R2","doi-asserted-by":"crossref","unstructured":"Shannon KM, Keith JF, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics.\u20081995;95:1\u20138","DOI":"10.1542\/peds.95.1.1"},{"key":"2021120819335477000_R3","doi-asserted-by":"crossref","unstructured":"Donato H, Vain N, Rendo P, et al. Effect of early versus late recombinant human erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Pediatrics.\u20082000;105:1066\u20131072","DOI":"10.1542\/peds.105.5.1066"},{"key":"2021120819335477000_R4","doi-asserted-by":"crossref","unstructured":"Maier RF, Obladen M, Muller-Hansen I, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr.\u20082002;141:8\u201315","DOI":"10.1067\/mpd.2002.124309"},{"key":"2021120819335477000_R5","doi-asserted-by":"crossref","unstructured":"Ohls RK. Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity. Paediatr Drugs.\u20082002;4:111\u2013121","DOI":"10.2165\/00128072-200204020-00004"},{"key":"2021120819335477000_R6","doi-asserted-by":"crossref","unstructured":"Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. J Pediatr.\u20081995;127:291\u2013297","DOI":"10.1016\/S0022-3476(95)70313-6"},{"key":"2021120819335477000_R7","doi-asserted-by":"crossref","unstructured":"Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol.\u20081999;19:403\u2013406","DOI":"10.1038\/sj.jp.7200244"},{"key":"2021120819335477000_R8","doi-asserted-by":"crossref","unstructured":"Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol.\u20081996;87:163\u2013168","DOI":"10.1016\/0029-7844(95)00386-X"},{"key":"2021120819335477000_R9","doi-asserted-by":"crossref","unstructured":"The Committee for the Classification of Retinopathy of Prematurity. An international classification for retinopathy of prematurity. Arch Ophthalmol.\u20081984;102:1130\u20131134","DOI":"10.1001\/archopht.1984.01040030908011"},{"key":"2021120819335477000_R10","doi-asserted-by":"crossref","unstructured":"Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 grams. J Pediatr.\u20081978;92:529\u2013534","DOI":"10.1016\/S0022-3476(78)80282-0"},{"key":"2021120819335477000_R11","doi-asserted-by":"crossref","unstructured":"Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am.\u20081986;33:179\u2013201","DOI":"10.1016\/S0031-3955(16)34975-6"},{"key":"2021120819335477000_R12","doi-asserted-by":"crossref","unstructured":"Vohr BR, O'Shea M, Wright LL. Longitudinal multicenter follow-up of high-risk infants: why, who, when, and what to assess. Semin Perinatol.\u20082003;27:333\u2013342","DOI":"10.1016\/S0146-0005(03)00045-4"},{"key":"2021120819335477000_R13","doi-asserted-by":"crossref","unstructured":"Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med.\u20082002;346:469\u2013467","DOI":"10.1056\/NEJMoa011931"},{"key":"2021120819335477000_R14","doi-asserted-by":"crossref","unstructured":"Zaffanello M, Franchini M, Rugolotto S. Recombinant human erythropoietin might induce strawberry haemangiomas in very-low-birthweight preterm infants. Acta Paediatr.\u20082003;92:1353\u20131354","DOI":"10.1111\/j.1651-2227.2003.tb00511.x"},{"key":"2021120819335477000_R15","doi-asserted-by":"crossref","unstructured":"Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int.\u20081995;47:740\u2013745","DOI":"10.1038\/ki.1995.113"},{"key":"2021120819335477000_R16","doi-asserted-by":"crossref","unstructured":"Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci.\u20082001;21:9733\u20139743","DOI":"10.1523\/JNEUROSCI.21-24-09733.2001"},{"key":"2021120819335477000_R17","doi-asserted-by":"crossref","unstructured":"Dame C, Bartmann P, Wolber E, Fahnenstich H, Hofmann D, Fandrey J. Erythropoietin gene expression in different areas of the developing human central nervous system. Dev Brain Res.\u20082000;125:69\u201374","DOI":"10.1016\/S0165-3806(00)00118-8"},{"key":"2021120819335477000_R18","doi-asserted-by":"crossref","unstructured":"Sire\u0301n A-L, Knerlich F, Poser W, Gleiter CH, Bru\u0308ck W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic\/hypoxic brain. Acta Neuropathol (Berl).\u20082001;101:271\u2013276","DOI":"10.1007\/s004010000297"},{"key":"2021120819335477000_R19","doi-asserted-by":"crossref","unstructured":"Juul SE. Erythropoietin in the central nervous system and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl.\u20082002;438:36\u201342","DOI":"10.1111\/j.1651-2227.2002.tb02904.x"},{"key":"2021120819335477000_R20","doi-asserted-by":"crossref","unstructured":"Chong ZZ, Kang J-Q, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol.\u20082003;138:1107\u20131118","DOI":"10.1038\/sj.bjp.0705161"},{"key":"2021120819335477000_R21","doi-asserted-by":"crossref","unstructured":"Wen TC, Sadamoto Y, Tanaka J, et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res.\u20082002;67:795\u2013803","DOI":"10.1002\/jnr.10166"},{"key":"2021120819335477000_R22","doi-asserted-by":"crossref","unstructured":"Erbayraktar S, Grasso G, Sfacteria A, t al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA.\u20082003;100:6741\u20136746","DOI":"10.1073\/pnas.1031753100"},{"key":"2021120819335477000_R23","doi-asserted-by":"crossref","unstructured":"Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA.\u20082002;99:5627\u20135631","DOI":"10.1073\/pnas.082097299"},{"key":"2021120819335477000_R24","doi-asserted-by":"crossref","unstructured":"Siren A-L, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA.\u20082001;98:4044\u20134049","DOI":"10.1073\/pnas.051606598"},{"key":"2021120819335477000_R25","doi-asserted-by":"crossref","unstructured":"Solaroglu I, Solaroglu A, Kaptanoglu E, Dede S, Haberal A, Beskonakli E, Kilinc K. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst.\u20082003;19:19\u201322","DOI":"10.1007\/s00381-002-0680-2"},{"key":"2021120819335477000_R26","doi-asserted-by":"crossref","unstructured":"Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res.\u20081999;46:543\u2013547","DOI":"10.1203\/00006450-199911000-00009"},{"key":"2021120819335477000_R27","doi-asserted-by":"crossref","unstructured":"Kwik-Uribe CL, Gietzen D, German JB, Golub MS, Keen CL. Chronic marginal iron intakes during early development in mice result in persistent changes in dopamine metabolism and myelin composition. J Nutr.\u20082000;130:2821\u20132830","DOI":"10.1093\/jn\/130.11.2821"},{"key":"2021120819335477000_R28","doi-asserted-by":"crossref","unstructured":"de Deungria M, Rao R, Wobken JD, Luciana M, Nelson CA, Georgieff MK. Perinatal iron deficiency decreases cytochrome c oxidase (CytOx) activity in selected regions of neonatal rat brain. Pediatr Res.\u20082000;48:169\u2013176","DOI":"10.1203\/00006450-200008000-00009"},{"key":"2021120819335477000_R29","doi-asserted-by":"crossref","unstructured":"Siddappa AJM, Rao RVB, Wobken JD, et al. Iron deficiency alters iron regulatory protein and iron transport protein expression in the perinatal rat brain. Pediatr Res.\u20082003;53:800\u2013807","DOI":"10.1203\/01.PDR.0000058922.67035.D5"},{"key":"2021120819335477000_R30","doi-asserted-by":"crossref","unstructured":"Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993\u20131994. Pediatrics.\u20082000;105:1216\u20131226","DOI":"10.1542\/peds.105.6.1216"},{"key":"2021120819335477000_R31","doi-asserted-by":"crossref","unstructured":"Hamill PV, Drizd TA, Johnson TA, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr.\u20081979;32:607\u2013629","DOI":"10.1093\/ajcn\/32.3.607"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/5\/1287\/1019499\/zpe01104001287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/5\/1287\/1019499\/zpe01104001287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T23:19:50Z","timestamp":1682810390000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/5\/1287\/67720\/Neurodevelopmental-Outcome-and-Growth-at-18-to-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,11,1]]},"published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2003-1129-l","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,1]]}}}